Details for New Drug Application (NDA): 012928
✉ Email this page to a colleague
NDA 012928 describes NOVRAD, which is a drug marketed by Lilly and is included in one NDA. Additional details are available on the NOVRAD profile page.
The generic ingredient in NOVRAD is levopropoxyphene napsylate anhydrous. Additional details are available on the levopropoxyphene napsylate anhydrous profile page.
The generic ingredient in NOVRAD is levopropoxyphene napsylate anhydrous. Additional details are available on the levopropoxyphene napsylate anhydrous profile page.
Summary for 012928
| Tradename: | NOVRAD |
| Applicant: | Lilly |
| Ingredient: | levopropoxyphene napsylate anhydrous |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 012928
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SUSPENSION;ORAL | Strength | EQ 50MG BASE/5ML | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Profile for product number 004
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | EQ 100MG BASE | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Profile for product number 006
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | EQ 50MG BASE | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
